Trial Search Results

Calcium Chloride for Prevention of Uterine Atony During Cesarean

In this pilot study, investigators will administer calcium chloride or placebo to pregnant women undergoing Cesarean delivery who have been identified as high risk for hemorrhage due to poor uterine muscle contraction, or atony. They will assess whether a single dose of calcium given immediately after the delivery of the fetus decreases the incidence of uterine atony and bleeding for the mother. The pharmacokinetics of calcium chloride in pregnant women will also be established. Data from this pilot study of 40 patients will be used to determine sample size and appropriateness of a larger randomized clinical trial.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Calcium Chloride
  • Drug: Placebo


Phase 1/Phase 2


Inclusion Criteria:

Pregnant female subjects at Lucile Packard Children's hospital / Stanford hospital
undergoing Cesarean will be screened for inclusion in the study based upon presence of at
least 2 risk factors for uterine atony/ postpartum hemorrhage. The risk factors include the

   - intrapartum Cesarean delivery

   - failed operative vaginal delivery with forceps or vacuum

   - magnesium infusion

   - chorioamnionitis

   - multiple gestation

   - polyhydramnios

   - preterm delivery <37 weeks

   - prior history of postpartum hemorrhage

   - labor induction or augmentation with oxytocin

   - advanced maternal age

   - obesity with body mass index >40

Exclusion Criteria:

   - a degree of case urgency to which taking time to consent for the study could
   compromise patient care, determined by anesthesiologist or obstetrician

   - patient age <18 years or >50 years

   - renal dysfunction with serum Creatinine > 1.0

   - abnormal cardiac function or history of arrhythmia

   - patient taking digoxin

   - patient currently taking a calcium channel blocker for a cardiovascular indication

Ages Eligible for Study

18 Years - 50 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brendan Carvalho, MBBCh, FRCA